HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy

D Lincoln; K Petoumenos; GJ Dore; R Finlayson; J Clemons; D Ellis; D Baker; J Kidd; R McFarlane; K Queetoumenos; M Law; D Smith; S Huffam; J Savage; S Morgan; P Knibbs; G Rogers; H Ree; H Magon; D Sowden; A Walker; D Orth; G Lister; J Chuah; R James; W Fankhauser; B Dickson; D Bradford; C Wilson; K Fairley; N Roth; B Eu; S Strecker; D Russell; H Wood; A Maijch; J Hoy; A Pierce; C McCormack; K Watson; J Anderson; R Moore; D Russell; G McGovern; R McNair; J Bal; N Medland; J Daye; S Mallal; M French; J Skett; D Maxwell; A Cain; P Rooney; S Taylor; D Couldwell; D Austin; M Block; D Quan; A Gowers; K Brown; S Simpson; C O'Connor; S Vong; MT Liang; D Allen; B Mulhall; D Smith; G Smith; J Armishaw; D Cooper; A Carr; J Miller; C Pell; R Rohrsheim

Journal article

HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy

D Lincoln, K Petoumenos, GJ Dore, R Finlayson, J Clemons, D Ellis, D Baker, J Kidd, R McFarlane, K Queetoumenos, M Law, D Smith, S Huffam, J Savage, S Morgan, P Knibbs, G Rogers, H Ree, H Magon, D Sowden Show all

HIV Medicine | Published : 2003

DOI: 10.1046/j.1468-1293.2003.00152.x

Abstract

Objectives. To assess the prevalence and risk factors for HBV and HCV coinfection in the Australia HIV Observational Database (AHOD), and examine outcomes of HIV disease following initiation of highly active antiretroviral therapy (HAART). Methods. Analyses were based on 2086 participants recruited to AHOD by September 2002. Of these, 1605 (77%) had been tested for HBV surface antigen, 1704 (82%) for anti-HCV antibody and 1453 (70%) for both. Demographic and clinical predictors of HBV and HCV coinfection were examined. The impact of HBV and HCV coinfection on HIV disease progression was assessed by Kaplan-Meier survival curves and Cox proportional hazard model of time to AIDS events and deat..

View full abstract